ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4

Background and aimsThe crosstalk between cancer stem cells (CSCs) and their niche is required for the maintenance of stem cell-like phenotypes of CSCs. Here, we identified E26 transformation-specific homologous factor (EHF) as a key molecule in decreasing the sensitivity of pancreatic cancer (PC) ce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2022-02, Vol.71 (2), p.357-371
Hauptverfasser:	Zhou, Tianxing, Liu, Jing, Xie, Yongjie, Yuan, Shuai, Guo, Yu, Bai, Weiwei, Zhao, Kaili, Jiang, Wenna, Wang, Hongwei, Wang, Haotian, Zhao, Tiansuo, Huang, Chongbiao, Gao, Song, Wang, Xiuchao, Yang, Shengyu, Hao, Jihui
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cancer therapies Chemotherapy Chromatin Clinical medicine Cohort Studies CXCL12 protein CXCR4 protein Dehydrogenases Disease Models, Animal Flow cytometry Gemcitabine Humans Hypoglycemic Agents - pharmacology Immunoprecipitation Medical prognosis Metastasis Mice Mice, Inbred BALB C Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Oct-4 protein Pancreas Pancreatic cancer Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pancreatic Stellate Cells - drug effects Pancreatic Stellate Cells - metabolism Phenotypes Pheochromocytoma cells Receptors, CXCR4 - metabolism Reverse transcription Rosiglitazone Rosiglitazone - pharmacology Sox9 protein Stellate cells Stem cell transplantation Stem cells Transcription Factors - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!